Oral Androgens in Man-3: Pharmacokinetics of Oral Testosterone With Concomitant Inhibition of 5α-Reductase by Dutasteride Short Title: ORAL T-3
The drug Lupron, will temporarily turn off the body's production of testosterone after two
weeks. At that point, we will administer testosterone by mouth on six days in the next two
weeks to see how much is absorbed and present in the bloodstream after administration. The
day Lupron is given, and for 24 days after that, subjects will take the second medication,
Dutasteride, which alters testosterone breakdown in the body. Fifteen days after the Lupron
shot, subjects will take the first formulation of testosterone by mouth and undergo blood
draws to see how much of this testosterone makes it into the blood stream and how long it
lasts. The next day(Day 2) subjects will take a larger dose of testosterone and undergo
blood draws. On study day 3, subjects will again take the larger dose of testosterone, this
time with a meal and undergo blood draws. During the 2nd week of the study, subjects will
repeat the testosterone doses, with a 2nd formulation of testosterone. The first two doses
of testosterone each week will be taken on an empty stomach, while the third will be taken
with breakfast. Please note that six study days: 1,2,3,8,9 and 10 will require repeated
blood draws over a 12 hour period.
Interventional
Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment
Elevations in serum testosterone
2 months
No
William J Bremner, MD, PhD
Principal Investigator
University of Washington
United States: Food and Drug Administration
04-4115-D
NCT00161421
March 2005
July 2006
Name | Location |
---|---|
University of Washington | Seattle, Washington 98195 |